Net sales grew 8.8% year-over-year, led by strong gains in EP/Ablation and Neurovascular, while operating profit declined 9.4% due to higher R&D and personnel costs. The full-year outlook is reaffirmed, and the dividend forecast was raised to ¥81.00 per share, including a commemorative payout.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.